Alzheimer's disease as type 3 diabetes: common pathophysiological mechanisms between Alzheimer's disease and type 2 diabetes
Open accessThe DOI matches its Crossref record; 150 of the 150 references it cites were found in a registry or an index.
Abstract
Globally, the incidence of type 2 diabetes mellitus (T2DM) and Alzheimer’s disease (AD) epidemics is increasing rapidly and has huge financial and emotional costs. The purpose of the current review article is to discuss the shared pathophysiological connections between AD and T2DM. Research findings are presented to underline the vital role that insulin plays in the brain’s neurotransmitters, homeostasis of energy, as well as memory capacity. The findings of this review indicate the existence of a mechanistic interplay between AD pathogenesis with T2DM and, especially, disrupted insulin signaling. AD and T2DM are interlinked with insulin resistance, neuroinflammation, oxidative stress, advanced glycosylation end products (AGEs), mitochondrial dysfunction and metabolic syndrome. Beta-amyloid, tau protein and amylin can accumulate in T2DM and AD brains. Given that the T2DM patients are not routinely evaluated in terms of their cognitive status, they are rarely treated for cognitive impairment. Similarly, AD patients are not routinely evaluated for high levels of insulin or for T2DM. Studies suggesting AD as a metabolic disease caused by insulin resistance in the brain also offer strong support for the hypothesis that AD is a type 3 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Free radicals and antioxidants in normal physiological functions and human disease
Valko, M., Leibfritz, D., Moncol, J., Cronin, M. T. D., Mazur, M., & Telser, J. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2006.07.001 · Cited by 14,269 · cited 2×
“It leads to oxidation of proteins, lipids and DNA, causing damage to the mitochondria, as well as induction of genetic mutations in DNA/RNA [91]).”
BackgroundSaeedi, P., Petersohn, I., Salpea, P., Malanda, B., Karuranga, S., Unwin, N., Colagiuri, S., Guariguata, L., Motala, A. A., Ogurtsova, K., et al. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107843 · Cited by 10,792 · cited 1×
“It is estimated that the global diabetes mellitus (DM) prevalence will rise from 9.3% (463 million people) in 2019 to 10.2% (578 million) by 2030 and 10.9% (700 million) by 2045 [8].”
BackgroundInfluentialHearing loss and cognitive decline in older adults
Lin, F. R., Yaffe, K., Xia, J., Xue, Q.-L., Harris, T. B., Purchase-Helzner, E., Satterfield, S., Ayonayon, H. N., Ferrucci, L., Simonsick, E. M., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.1868 · Cited by 4,017
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459 · cited 1×
“The strongest genetic risk factor for AD is the e4 allele of apolipoprotein E (APOE4) relative to the e3 allele and the protective e2 allele [5,6].”
BackgroundType 2 diabetes: principles of pathogenesis and therapy
Stumvoll, M., Goldstein, B. J., & van Haeften, T. W. (2005) · The Lancet · doi:10.1016/s0140-6736(05)61032-x · Cited by 2,662 · cited 2×
“This dysfunction means that the secretion of insulin by the β-cells of the pancreatic islets (β-cell dysfunction) as well as the action of insulin on insulin-sensitive tissues such as the liver, adipose tissue and muscle do not function normally for the body (insulin resistance) [9].”
BackgroundProtein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade
Chiti, F., & Dobson, C. M. (2017) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061516-045115 · Cited by 2,629 · cited 1×
“AD and T2DM are both diseases that involve the formation of amyloid in various parts of the body [42,43].”
BackgroundAdvanced Glycation End Products: Sparking the Development of Diabetic Vascular Injury
Goldin, A., Beckman, J. A., Schmidt, A. M., & Creager, M. A. (2006) · Circulation · doi:10.1161/circulationaha.106.621854 · Cited by 2,261 · cited 1×
“These products are protein molecules or peptides that are formed as a result of the Maillard reaction, meaning they become glycated as a result of their exposure to sugars [105].”
BackgroundTau in physiology and pathology
Wang, Y., & Mandelkow, E. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2015.1 · Cited by 2,251 · cited 1×
“In its normal state, tau protein is responsible for microtubule stability and regulating intracellular signaling [63–66].”
Background2021 Alzheimer's disease facts and figures
(2021) · Alzheimer's & Dementia · doi:10.1002/alz.12328 · Cited by 2,201
Diabetes mellitus and the risk of dementia: The Rotterdam Study
Ott, A., Stolk, R. P., van Harskamp, F., Pols, H. A. P., Hofman, A., & Breteler, M. M. B. (1999) · Neurology · doi:10.1212/wnl.53.9.1937 · Cited by 2,175 · cited 1×
“Insulin resistance affects the way insulin works in target tissues and cells, leading to the well-known phenomenon of hyperglycemia, a condition in which too much glucose circulates in the blood plasma and characterizes T2DM [9] T2DM has also been associated with an increased risk of dementia [10,11] and of AD by 45–9…”
Background
Cited by
Items 301–346 of 346
Ji, W., Wang, C., Wang, X., Liang, Y., Qiu, S., & Wang, S. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-05883-z
Shan, S., Wu, J., Zhou, J., ZHANG, C., Xu, C., Zha, J., Ying, J., Zhu, Y., Hu, S., Song, P., et al. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02167-3
“Similarly, diabetes, another well-established risk factor for dementia, shares overlapping pathological pathways with depression [12, 13].”
Barnabas, S. S., Well, E. Z., Kutshak, I. P., Ponan, D. A., & Philip, N. (2026) · Letters in Applied NanoBioScience · doi:10.33263/lianbs151.002
Sathya, M., Sangeetha, P., Selvi, V. S., & Rekha, K. (2026) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-026-01420-w
When the eye mirrors the brain : Common molecular signatures of diabetic neurodegeneration
Deàs-Just, A. (2026) · Tesis Doctorals en Xarxa (Consorci de Serveis Universitaris de Catalunya)
Juni, J. E., Burns, J. M., Salat, D. H., Hill, D., Tally, S., Martin, J. S., Devous, M. D., & Moriarty, P. M. (2026) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/15333175261451918
Targeting microglia: A new strategy for the treatment of Alzheimer's disease
Zheng, M., Yang, M., Su, W., Tian, L., & Gao, W. (2026) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2026.578966
Guan, Y., Li, Q., Zhi, S., Ni, X., & Wang, X. (2026) · Journal of Radiation Research and Applied Sciences · doi:10.1016/j.jrras.2026.102428 · Cited by 1
Tao, L., Liu, Y., Li, J., Zhang, J., Zhao, H., Luo, K., Gao, Y., Mu, J., Yang, Q., & Yan, Z. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1818219
“Given these shared pathways, Michailidis et al. have systematically characterized AD as T3DM, emphasizing the overlapping pathophysiological signatures between AD and T2DM (22).”
Larrea, A., Naji, M., Gulak, M., Torrecilla, M., & Barreda‐Gómez, G. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48050498
“This relationship is mechanistically so robust that the brain-specific insulin resistance observed in AD has been proposed under the term "type 3 diabetes," reflecting the continuum between peripheral metabolic dysfunction and central neurodegeneration [166,167].”
The bidirectional mechanistic links between Alzheimer’s disease and cardiovascular disease
You, J., & Yang, J. (2026) · Neurological Sciences · doi:10.1007/s10072-026-09151-9
Pietilä, E. M., Mira, K., Helin, S., Snellman, A., Matti, V., Antti, J., Rinne, J. O., & Ekblad, L. L. (2026) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2026.06.004
Yang, L., Zeng, J., Luwen, H., & Li, L. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261460745 · Cited by 1
“33 – 37 Projections for 2035 illustrate a continuing divergence, serving as a report card on both current and future health system preparedness.”
Sánchez-Thomas, R., Bautista-Perez, S. M., Santana-Martínez, R. A., Silva‐Islas, C. A., Figueroa, A., Barrera‐Oviedo, D., & Maldonado, P. D. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44173-8.00015-2
García-Zamora, M., Pardo, J., Esteve, M., Martinez-Gracia, A., Cháfer‐Pericás, C., & Falcó, A. (2026) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70379
Rao, R. V., Subramaniam, K. G., Gregory, J., Bredesen, A. L., Coward, C., Okada, S., Kelly, L., & Bredesen, D. E. (2026) · Nutrients · doi:10.3390/nu18132206
“This “type 3 dia-betes” phenotype reflects brain insulin resistance and impaired mitochondrial oxidation, ultimately contributing to energetic failure and synaptic dysfunction [77,132,133].”
Özbek, H., Özer, E., Çeçen, Ö., Yuca, H., Güvenalp, Z., & Karakaya, S. (2026) · Chemistry & Biodiversity · doi:10.1002/cbdv.71519
Multisystem Benefits of GLP-1 Microdosing: A Narrative Review
Panlilio, M. A., Piserchio, N., Hennessey, M., Torres, K., Khan, S., & Choy, L. (2026) · Cureus · doi:10.7759/cureus.113635
“Other studies have shown that diabetic patients being treated with GLP-1 RAs have a reduced risk of developing PD, which suggests potential neuroprotective benefits [27,28].”
Rajendram, R., Patel, V. B., & Preedy, V. R. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-30263-3.00011-7
Brain Health Across the Lifespan: Nutritional Interventions and Physical Exercise for Healthy Aging
(2026) · Frontiers research topics · doi:10.3389/978-2-8325-8456-9
Cognitive links with brain insulin signaling in metabolism: A new narrative
Yaribeygi, H., & Forouzanmehr, B. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-30263-3.00030-0
Geng, D., Ruan, X., Yang, H., Zhou, L., Qu, M., He, Y., Tian, Y., Ma, Y., Mi, W., & Sun, M. (2026) · Aging Clinical and Experimental Research · doi:10.1007/s40520-026-03459-4
Mózes, N., Lipécz, Á., Csípő, T., Fazekas‐Pongor, V., Major, D., Hung, W. Y., Zábó, V., Csík, B., Fehér, Á., Bérczi, B., et al. (2026) · Nutrients · doi:10.3390/nu18162594
Phillips, W. T., & Schwartz, J. G. (2026) · Frontiers in Neuroscience · doi:10.3389/fnins.2026.1897376 · Cited by 1
“Managing hyperglycemia and insulin resistance is considered a potential method to slow cognitive decline (Michailidis et al., 2022).”
Venuti, M. T., Brandalise, F., Cappelletti, M., Speciani, A. F., Speciani, M. C., Priori, E. C., Giammello, F., Roda, E., Rossi, P., & Ratto, D. (2026) · Metabolic Brain Disease · doi:10.1007/s11011-026-01956-z
“Due to its strong metabolic component, some authors also refer to AD as “type 3 diabetes” (Michailidis et al. 2022; Kciuk et al. 2024).”
Spires‐Jones, T. L. (2026) · Oxford University Press eBooks · doi:10.1093/9780198995296.003.0002
Zhou, R., Cui, S., Shang, S., Wei, S., Gao, L., Dang, L., Wang, X., Wang, J., Qu, Q., & Deng, Y. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113540
He, S., Han, X., Chen, J., Li, C., Li, J., Zhou, Y., Mao, W., Zhang, X., Chen, Y., Zhan, J., et al. (2026) · Metabolic Brain Disease · doi:10.1007/s11011-026-01959-w
“…is critical, as it aligns with the clinical scenario where managing comorbid conditions (like diabetes) in AD patients can slow pro - gression and improve quality of life (Michailidis et al. 2022; Arnold et al. 2018), even if the core neurodegenerative pro - cess persists (Tumminia et al. 2018).”
Singh, R., Paliwal, T., Joshi, R., Paliwal, V., Dubey, P., Bhardwaj, S., Jain, S., Paliwal, S., & Sharma, S. K. (2026) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2026.154524
Bautista, H. L. R. (2026) · Knowledge UdeS (Institutional Deposit of the University of Sherbrooke) · doi:10.71892/11143/1947
Macesic, M. V., Lalic, K. S., Lukić, L., Milicic, T. J., Stojmenović, G. M., Stojković, T., Gajović, J. S., Stoiljkovic, M. M., Milin-Lazovic, J. S., Milovancevic, M. M., et al. (2026) · Diabetology · doi:10.3390/diabetology7090186
Joo, B., Kim, D.-U., Kweon, B., & Bae, G. (2026) · Brain Sciences · doi:10.3390/brainsci16101005
“…of transcriptomic datasets specific to diabetic cognitive impairment, AD-related datasets were additionally incorporated into the analysis, based on shared pathological mechanisms between the two conditions, including chronic neuroinflammation, neuronal apoptosis, and brain insulin resistance [70].”
Fakorede, S., Lateef, O. M., Udefa, A. L., Ajagbe͓, A. O., Roy, S., Akosile, P. O., Awobona, T. A., & Anyanwu, G. E. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-06237-5
Should Diabetes Be Considered “Pancreatic Alzheimer’s Disease?”
Bullock, H., & Weaver, D. F. (2026) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2026.10696
Keleş, T., Akkaya, D., Özel, A., Aksel, A. B., Eyi, T., Yıldırım, B. N., & Bıyıklıoğlu, Z. (2026) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2026.147760
From Blood Sugar To Brain Health: Understanding Type 3 Diabetes and Alzheimer’s
Moitra, R., Nayak, S. S., Lokhandwala, Z., Desai, V., Patel, H. P., Patel, N., Sanjaykumar, D. V., & Patel, K. J. (2025) · Journal of Neonatal Surgery · Cited by 1
Cakmak, R. K., Johnson, B. S., Ercin, N., Beşli, N., Beker, M., & Kılıç, Ü. (2026) · Pharmaceuticals · doi:10.3390/ph19101573
“Meanwhile, amyloid beta binds to IR and IGFR, shows an antagonistic effect, and creates an inflammatory response [30].”
Liu, W., Xu, B., 任晓虎, Yang, C., Li, G., Zhang, Z., Yang, X., & Liu, J. (2026) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2026.10.013
Shi, H., Ke, Z., Wang, B., Zhang, X., Gui, Y., Zhang, H., & Liang, R. (2026) · Experimental Neurology · doi:10.1016/j.expneurol.2026.116091
Diabetes Mellitus: Review of the Common, Rare, and Uncommon (Conceptual and Metaphorical) Types
Pliszka, M., & Szablewski, L. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27219611
Song, M., Liu, A., Liang, H., Yang, Q., Zhang, B., Cui, J., & Qiu, Y. (2026) · Frontiers in Neurology · doi:10.3389/fneur.2026.1817059
Alzheimer and cerebral metabolic fragility
Colonnese, A., & Panzironi, R. (2026) · doi:10.68559/lsh.libro.15
Alzheimer et fragilité du métabolisme cérébral
Colonnese, A., & Panzironi, R. (2026) · doi:10.68559/lsh.libro.15.fr
Alzheimer und die Fragilität des zerebralen Stoffwechsels
Colonnese, A., & Panzironi, R. (2026) · doi:10.68559/lsh.libro.15.de
Alzheimer y fragilidad del metabolismo cerebral
Colonnese, A., & Panzironi, R. (2026) · doi:10.68559/lsh.libro.15.es
Alzheimer e fragilità del metabolismo cerebrale
Colonnese, A., & Panzironi, R. (2026) · doi:10.68559/lsh.libro.15.it
Metadata
- Authors
- Michailidis, M., Moraitou, D., Tata, D. A., Kalinderi, K., Papamitsou, T., & Papaliagkas, V.
- Affiliations
- Laboratory of Psychology, School of Psychology, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece
- Aristotle University of Thessaloniki (GR)
- International Hellenic University (GR)
- Corresponding author
- Papaliagkas, Vasileios
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-02-28
- Volume
- 23
- Issue
- 5
- Pages
- 2687
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC8910482
- OpenAlex
- W4214581316
- Cited by
- 330
- References
- 150
- Citations by year
- 2026: 79 · 2025: 110 · 2024: 71 · 2023: 61 · 2022: 9
- FWCI
- 8.63
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Advanced Glycation End Products research
- Keywords
- Alzheimer's disease, type 2 diabetes, type 3 diabetes, insulin resistance, insulin signaling, neuroinflammation, oxidative stress, advanced glycation end products, mitochondrial dysfunction, metabolic syndrome, amyloid-beta, tau protein, amylin, cognitive impairment, brain energy homeostasis
- MeSH terms
- Alzheimer Disease, Brain, Diabetes Mellitus, Type 2, Humans, Insulin, Insulin Resistance, Amyloid beta-Peptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
